JP6320447B2 - 前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 - Google Patents
前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 Download PDFInfo
- Publication number
- JP6320447B2 JP6320447B2 JP2016088283A JP2016088283A JP6320447B2 JP 6320447 B2 JP6320447 B2 JP 6320447B2 JP 2016088283 A JP2016088283 A JP 2016088283A JP 2016088283 A JP2016088283 A JP 2016088283A JP 6320447 B2 JP6320447 B2 JP 6320447B2
- Authority
- JP
- Japan
- Prior art keywords
- gastric cancer
- gastric
- tissue sample
- detecting
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims description 51
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims description 40
- 206010017758 gastric cancer Diseases 0.000 title claims description 39
- 201000011549 stomach cancer Diseases 0.000 title claims description 39
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 claims description 64
- 210000001519 tissue Anatomy 0.000 claims description 62
- 239000000523 sample Substances 0.000 claims description 54
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 claims description 52
- 230000002496 gastric effect Effects 0.000 claims description 46
- 210000002784 stomach Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 230000009870 specific binding Effects 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 22
- 206010019375 Helicobacter infections Diseases 0.000 claims description 15
- 210000001156 gastric mucosa Anatomy 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 239000007850 fluorescent dye Substances 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 108700026220 vif Genes Proteins 0.000 claims 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 18
- 229940037467 helicobacter pylori Drugs 0.000 description 17
- 241000590002 Helicobacter pylori Species 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000004907 gland Anatomy 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 5
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 108091008104 nucleic acid aptamers Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102100025933 Cancer-associated gene 1 protein Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000933825 Homo sapiens Cancer-associated gene 1 protein Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012325 curative resection Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016088283A JP6320447B2 (ja) | 2016-04-26 | 2016-04-26 | 前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 |
| PCT/JP2017/016543 WO2017188315A1 (ja) | 2016-04-26 | 2017-04-26 | 早期胃癌検出キット及びその使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016088283A JP6320447B2 (ja) | 2016-04-26 | 2016-04-26 | 前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017195803A JP2017195803A (ja) | 2017-11-02 |
| JP2017195803A5 JP2017195803A5 (enExample) | 2018-01-11 |
| JP6320447B2 true JP6320447B2 (ja) | 2018-05-09 |
Family
ID=60159652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016088283A Active JP6320447B2 (ja) | 2016-04-26 | 2016-04-26 | 前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6320447B2 (enExample) |
| WO (1) | WO2017188315A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102627788B1 (ko) * | 2018-06-21 | 2024-01-23 | 고리츠다이가쿠호징 나고야시리츠다이가쿠 | 위암 바이오마커 및 그 용도 |
| JP7150312B2 (ja) * | 2018-07-31 | 2022-10-11 | 学校法人北里研究所 | 胃癌細胞におけるｋｋ－ｌｃ－１の発現を予測する方法及びキット |
| JP6797423B2 (ja) * | 2018-12-20 | 2020-12-09 | 学校法人北里研究所 | 胃組織試料が前癌状態であるか否かを判定する方法及びキット |
| CN109628457B (zh) * | 2019-02-03 | 2021-12-10 | 淮海工学院 | 单链dna核酸适配体及其筛选方法与用途 |
| CN112661812B (zh) * | 2021-03-17 | 2021-06-15 | 南京鼓楼医院 | 一种kk-lc-1抗原靶向结合肽及其衍生物、探针与应用 |
| WO2024048753A1 (ja) * | 2022-09-02 | 2024-03-07 | 学校法人北里研究所 | ヘリコバクター・ピロリ除菌後の患者が胃癌を発症するリスクを評価する方法、ポリヌクレオチド及びキット |
| CN117700493A (zh) * | 2023-12-20 | 2024-03-15 | 南京鼓楼医院 | 一种kk-lc-1靶向结合蛋白及其衍生物、试剂盒和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6707248B2 (ja) * | 2013-12-05 | 2020-06-10 | 学校法人北里研究所 | 胃癌細胞の検出方法、及び胃癌細胞検出キット |
| JP6028253B2 (ja) * | 2015-01-28 | 2016-11-16 | 学校法人北里研究所 | 癌細胞の検出方法及び癌細胞検出キット |
-
2016
- 2016-04-26 JP JP2016088283A patent/JP6320447B2/ja active Active
-
2017
- 2017-04-26 WO PCT/JP2017/016543 patent/WO2017188315A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017188315A1 (ja) | 2017-11-02 |
| JP2017195803A (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6320447B2 (ja) | 前癌状態の胃癌検出キット及び前癌状態の胃癌細胞の検出方法 | |
| Paulin et al. | Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease | |
| US10712343B2 (en) | Molecular analysis of tumor samples | |
| Zakhary et al. | Impact of PIVKA-II in diagnosis of hepatocellular carcinoma | |
| Ma et al. | The prognostic values of CA125, CA19. 9, NSE, AND SCC for stage I NSCLC are limited | |
| ES2856979T3 (es) | Procedimientos de identificación de un individuo en función de si se va a tratar con quimioterapia en base a moléculas marcadoras y usos relacionados | |
| Ellingsen et al. | Clinical activity of combined telomerase vaccination and pembrolizumab in advanced melanoma: results from a phase I trial | |
| Park et al. | Clinicopathological features and prognostic significance of HER2 expression in gastric cancer | |
| Coosemans et al. | Increased immunosuppression is related to increased amounts of ascites and inferior prognosis in ovarian cancer | |
| WO2016049045A1 (en) | Pancreatic cancer diagnostic | |
| JP7150312B2 (ja) | 胃癌細胞におけるｋｋ－ｌｃ－１の発現を予測する方法及びキット | |
| JP6361943B2 (ja) | 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット | |
| JP6707248B2 (ja) | 胃癌細胞の検出方法、及び胃癌細胞検出キット | |
| RU2010149266A (ru) | Улучшенные способы иммуноанализа | |
| KR102599695B1 (ko) | 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도 | |
| JP2021524576A (ja) | がんの診断及び治療のための組成物及び方法 | |
| Potempa-Jeziorowska | Salivary biomarkers for monitoring the course of cancer development–real perspectives | |
| Jafari et al. | Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer | |
| Voronova et al. | Evaluation and diagnostic potential of plasma biomarkers in bladder cancer | |
| Pradhan et al. | Immunodiagnostics: A Perspective on Sensitivity, Specificity, and Stability of Tumor Antigens | |
| Oni et al. | Detection of incipient pancreatic cancer with novel tumor-specific antibodies in mouse models | |
| Hanif et al. | Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients | |
| JP2004511758A (ja) | 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法 | |
| 島田英昭 | Combinational antibody detection approach increases the clinical validity of colorectal cancer screening | |
| WO2022152732A1 (en) | Prognostic value of biomarkers in patients with non-small cell lung cancer having stable disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171120 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171120 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20171120 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20171206 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180307 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180320 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6320447 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |